WuXi Biologics (Cayman) Balance Sheet Health
Financial Health criteria checks 5/6
WuXi Biologics (Cayman) has a total shareholder equity of CN¥44.0B and total debt of CN¥2.1B, which brings its debt-to-equity ratio to 4.9%. Its total assets and total liabilities are CN¥56.6B and CN¥12.6B respectively. WuXi Biologics (Cayman)'s EBIT is CN¥3.9B making its interest coverage ratio -64.8. It has cash and short-term investments of CN¥11.2B.
Key information
4.9%
Debt to equity ratio
CN¥2.15b
Debt
| Interest coverage ratio | -64.8x |
| Cash | CN¥11.24b |
| Equity | CN¥44.02b |
| Total liabilities | CN¥12.56b |
| Total assets | CN¥56.58b |
Recent financial health updates
Here's Why WuXi Biologics (Cayman) (HKG:2269) Can Manage Its Debt Responsibly
Apr 15
Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?
Nov 26These 4 Measures Indicate That WuXi Biologics (Cayman) (HKG:2269) Is Using Debt Reasonably Well
Aug 26Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?
Mar 25Is WuXi Biologics (Cayman) (HKG:2269) A Risky Investment?
Dec 09WuXi Biologics (Cayman) (HKG:2269) Seems To Use Debt Quite Sensibly
Sep 08Recent updates
Here's Why WuXi Biologics (Cayman) (HKG:2269) Can Manage Its Debt Responsibly
Apr 15Why Investors Shouldn't Be Surprised By WuXi Biologics (Cayman) Inc.'s (HKG:2269) 25% Share Price Surge
Mar 04Things Look Grim For WuXi Biologics (Cayman) Inc. (HKG:2269) After Today's Downgrade
Dec 08Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?
Nov 26Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)
Nov 10What Does WuXi Biologics (Cayman) Inc.'s (HKG:2269) Share Price Indicate?
Sep 26These 4 Measures Indicate That WuXi Biologics (Cayman) (HKG:2269) Is Using Debt Reasonably Well
Aug 26WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Could Be 24% Below Their Intrinsic Value Estimate
Aug 10Is WuXi Biologics (Cayman) Inc. (HKG:2269) Potentially Undervalued?
Jun 19Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)
May 12Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?
Mar 25At HK$52.00, Is WuXi Biologics (Cayman) Inc. (HKG:2269) Worth Looking At Closely?
Mar 13Does WuXi Biologics (Cayman) (HKG:2269) Deserve A Spot On Your Watchlist?
Feb 13An Intrinsic Calculation For WuXi Biologics (Cayman) Inc. (HKG:2269) Suggests It's 29% Undervalued
Jan 30Is WuXi Biologics (Cayman) (HKG:2269) A Risky Investment?
Dec 09Why WuXi Biologics (Cayman) Inc. (HKG:2269) Could Be Worth Watching
Nov 20With EPS Growth And More, WuXi Biologics (Cayman) (HKG:2269) Makes An Interesting Case
Nov 08Is WuXi Biologics (Cayman) Inc. (HKG:2269) Trading At A 47% Discount?
Oct 27WuXi Biologics (Cayman) (HKG:2269) Seems To Use Debt Quite Sensibly
Sep 08Is Now The Time To Look At Buying WuXi Biologics (Cayman) Inc. (HKG:2269)?
Aug 15We Ran A Stock Scan For Earnings Growth And WuXi Biologics (Cayman) (HKG:2269) Passed With Ease
Aug 02Estimating The Intrinsic Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)
Jun 29What Does WuXi Biologics (Cayman) Inc.'s (HKG:2269) Share Price Indicate?
May 16Here's Why I Think WuXi Biologics (Cayman) (HKG:2269) Might Deserve Your Attention Today
May 03Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?
Apr 21An Intrinsic Calculation For WuXi Biologics (Cayman) Inc. (HKG:2269) Suggests It's 42% Undervalued
Mar 26Financial Position Analysis
Short Term Liabilities: 2269's short term assets (CN¥21.2B) exceed its short term liabilities (CN¥7.6B).
Long Term Liabilities: 2269's short term assets (CN¥21.2B) exceed its long term liabilities (CN¥4.9B).
Debt to Equity History and Analysis
Debt Level: 2269 has more cash than its total debt.
Reducing Debt: 2269's debt to equity ratio has increased from 0% to 4.9% over the past 5 years.
Debt Coverage: 2269's debt is well covered by operating cash flow (217.4%).
Interest Coverage: 2269 earns more interest than it pays, so coverage of interest payments is not a concern.